You are here

AusPAR: Durvalumab

Related information


How to access a pdf or Word document

*Large file warning: Attempting to open large files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open from there.

Australian Public Assessment Report

19 April 2021
AusPAR Details
AusPAR
Active Ingredient
Durvalumab
Product Name
Imfinzi
Sponsor
AstraZeneca Pty Ltd
Submission Number
PM-2019-04661-1-4
Submission Type
Extension of indications
Decision
Approved
AusPAR Date
22 March 2021
Publication Date

19 April 2021